CIAC101
CIAC101 is a potent and brain-penetrant TLR4 antagonist with an IC50 of 17.0 nM in NO assay. CIAC101 blocks Lipopolysaccharides (HY-D1056) (LPS)-induced NF-κB activation and reduces the expression of pro-inflammatory mediators (iNOS, IL-1β, TNF-α, and IL-6). CIAC101 robust antineuroinflammatory activity with efficacy against drug-evoked neurobehavioral adaptations. CIAC101 can be used for the research of addiction and neurological disease.
For research use only. We do not sell to patients.
- CAS No.: 3122563-80-5
- Formula: C24H29NO4
- Molecular Weight:395.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
TLR4 17 nM (IC50) |
NF-κB |
iNOS |
TNF-α |
IL-1β |
IL-6 |
In Vitro
CIAC101 inhibits Lipopolysaccharides (HY-D1056) (LPS)-induced NO overproduction in microglia BV-2 cells with an IC50 of 17 nM[1].
CIAC101 (0.1 nM-10 μM; 24 h) dose-dependently blocks LPS-induced NF-κB activation (IC50 of 65.5 nM) and reduces the expression of pro-inflammatory mediators in HEK-BluehTLR4 cells. CIAC101 does not show significant cytotoxicity[1].
In a BV-2 NF-κB luciferase reporter cellline, CIAC101 (0.1 nM-10 μM; 24 h) dose-dependently suppresses LPS-induced NF-κB activation without apparent cytotoxicity, with an IC50 of 90.2 nM[1].
In the BV-2 microglial model challenged with LPS, CIAC101 (0.01-1 μM; 24 h) reduces LPS-evoked mRNA expression of iNOS, IL-1β, TNF-α, and IL-6 in a concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BV-2 microglial were treated with 200 ng/mL LPS
-
Concentration:0.01 μM, 0.1 μM, 1 μM
-
Incubation Time:24 h
-
Result:Reduced LPS-evoked mRNA expression of iNOS, IL-1β, TNF-α, and IL-6.
Parmacokinetics
| Species | Dose | Route | Note | Cmax | T1/2 | CL | Vd | AUC0-inf | Tmax | F |
|---|---|---|---|---|---|---|---|---|---|---|
| Mice | 2 mg/kg | i.v. | 文献审核 | 109 ng/mL | 2.83 h | 326 mL/min/kg | 51.3 L/kg | 363 ng·h/mL | / | / |
| Mice | 20 mg/kg | p.o. | 文献审核 | 64.3 ng/mL | 5.16 h | / | / | 115 ng·h/mL | 0.25 h | 9.05 % |
In Vivo
CIAC101 (20 mg/kg; i.p.; daily; for 14 days) is well tolerated with no evidence of acute systemic or organ toxicity in Balb/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Balb/c mice (6-8 weeks; 22-25 g) (METH-induced neuroinflammation and addiction-like behaviors)[1]
-
Dosage:0.005 mg/kg, 0.02 mg/kg, 0.2 mg/kg
-
Administration:Intraperitoneal (i.p.)
-
Result:Significantly reduced METH-induced behavioral sensitization and conditioned place preference (CPP).
Also attenuated microglial activation and proinflammatory gene expression (IL-1β, TNF-α, and IL-6) in the medial prefrontal cortex (mPFC) and ventral tegmental area (VTA).
Chemical Information
-
CAS No. 3122563-80-5
-
Molecular Weight 395.49
-
Formula C24H29NO4
-
SMILES
O=C1[C@](OC2=C(OCC(C)C)C=CC3=C24)([H])[C@]54CCN(CC6CC6)[C@](C3)([H])[C@@]5(O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)